{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045752205696.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1046/j.1365-2893.2000.00215.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2893.2000.00215.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2893.2000.00215.x"}}],"dc:title":[{"@value":"Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>We analysed data from a multicentre interferon (IFN) treatment trial to evaluate symptoms in patients with chronic hepatitis C and to identify factors that might predict development of debilitating IFN side‐effects. Two hundred and twenty‐two patients (120 US, 102 French) received 3 or 5 million units (MU) of IFN‐α three times weekly (t.i.w.) for 3 months. Those who had detectable hepatitis C virus (HCV) RNA, as detected by the branched DNA signal amplification (bDNA) assay, at 3 months were intensified to daily therapy, while patients who were bDNA negative continued t.i.w. dosing for the subsequent 3 months of treatment. Symptoms were assessed at baseline, and adverse effects were evaluated at 6 months of therapy. Prior to treatment, the most common symptom that interfered with daily functioning was fatigue, occurring in 25% of patients. The frequency of debilitating fatigue, myalgia, arthralgia, headache, the presence of dry eyes and dry mouth, and use of antidepressant medication increased significantly from baseline to 6 months of IFN therapy (all <jats:italic>P</jats:italic> < 0.01). In multivariate analysis, the development of a debilitating side‐effect at 6 months of treatment was associated with the presence of that symptom prior to therapy in all cases. Symptoms and adverse effects varied by gender and country. Compared with patients maintained on t.i.w. dosing, those who were dose intensified to daily IFN reported more debilitating fatigue, malaise, myalgia, arthralgia, fever, nausea, and headache, and the presence of dry mouth (all <jats:italic>P</jats:italic> < 0.05). In conclusion, patient characteristics, including pretreatment symptoms, gender and nationality, as well as daily IFN dosing are associated with the development of debilitating adverse effects on IFN therapy.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137045752205700","@type":"Researcher","foaf:name":[{"@value":"Cotler"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045752205699","@type":"Researcher","foaf:name":[{"@value":"Wartelle"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045752205701","@type":"Researcher","foaf:name":[{"@value":"Larson"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045752205697","@type":"Researcher","foaf:name":[{"@value":"Gretch"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045752205696","@type":"Researcher","foaf:name":[{"@value":"Jensen"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045752205698","@type":"Researcher","foaf:name":[{"@value":"Carithers Jr"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13520504"},{"@type":"EISSN","@value":"13652893"}],"prism:publicationName":[{"@value":"Journal of Viral Hepatitis"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2000-05","prism:volume":"7","prism:number":"3","prism:startingPage":"211","prism:endingPage":"217"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2893.2000.00215.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2893.2000.00215.x"}],"createdAt":"2003-03-12","modifiedAt":"2023-10-29","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050564285802714240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1"},{"@value":"Depressive symptoms as a side effect of Interferon-alpha therapy induced by induction of indoleamine 2,3-dioxygenase 1"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185477366784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Guidelines for the Management of Hepatitis <scp>C</scp> Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661711231872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679474195072","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Quinolinic Acid Decreases Mental Activity in Mice by Damaging Brain Neurons through the Activation of N-methyl-D-aspartate Receptors: Proposed Relationship to Human Mental Fatigue"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771529088","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment Guidelines of Hepatitis C"},{"@language":"ja","@value":"C型肝炎治療ガイドライン（第1版）"},{"@language":"ja-Kana","@value":"Cガタ カンエン チリョウ ガイドライン(ダイ1ハン)"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1046/j.1365-2893.2000.00215.x"},{"@type":"CROSSREF","@value":"10.1038/srep29920_references_DOI_CVB5Wc1lhcc8G62tgVp40XMe9IV"},{"@type":"CROSSREF","@value":"10.1248/jhs.57.153_references_DOI_CVB5Wc1lhcc8G62tgVp40XMe9IV"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_CVB5Wc1lhcc8G62tgVp40XMe9IV"},{"@type":"CROSSREF","@value":"10.1111/hepr.12020_references_DOI_CVB5Wc1lhcc8G62tgVp40XMe9IV"},{"@type":"CROSSREF","@value":"10.1186/1471-230x-12-155_references_DOI_CVB5Wc1lhcc8G62tgVp40XMe9IV"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_CVB5Wc1lhcc8G62tgVp40XMe9IV"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.355_references_DOI_CVB5Wc1lhcc8G62tgVp40XMe9IV"}]}